SCHEMBL6100788

SCHEMBL6100788

CN(C)c1ccnc2sc(C(=O)O)c(N)c12

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.80
HTT P42858 7/20 0.80
KDM4E B2RXH2 6/20 0.80
CDK8 P49336 5/20 0.80
CDK19 Q9BWU1 3/20 0.80
NPC1 O15118 2/20 0.74
RAB9A P51151 2/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
LMNA P02545 2/20 0.74
STAT1 P42224 1/20 0.74
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
HPGD P15428 3/20 0.67
ALOX15 P16050 2/20 0.67
TSHR P16473 2/20 0.67
NPSR1 Q6W5P4 2/20 0.67
LIMK1 P53667 1/20 0.52
NCOA1 Q15788 1/20 0.50
NCOA3 Q9Y6Q9 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12562445 0.89 ALDH1A1 (0.80) ALDH1A1HTTKDM4ECDK8CDK19
SCHEMBL426655 0.89 CDK8 (1.00) ALDH1A1HTTKDM4ECDK8CDK19
SCHEMBL17485804 0.85 ALDH1A1 (1.00) ALDH1A1HTTKDM4ECDK8CDK19
SCHEMBL8242540 0.85 ALDH1A1 (0.74) ALDH1A1HTTKDM4ECDK8CDK19
SCHEMBL8242756 0.85 ALDH1A1 (0.74) ALDH1A1HTTKDM4ECDK8CDK19
SCHEMBL8242094 0.83 ALDH1A1 (0.63) ALDH1A1HTTKDM4ECDK8CDK19
SCHEMBL16071457 0.82 ALDH1A1 (0.72) ALDH1A1HTTKDM4ECDK8CDK19
SCHEMBL8243906 0.82 ALDH1A1 (0.58) ALDH1A1HTTKDM4ECDK8CDK19
SCHEMBL2896099 0.81 LIMK1 (0.78) ALDH1A1HTTKDM4ECDK8CDK19
SCHEMBL429541 0.81 ALDH1A1 (1.00) ALDH1A1HTTKDM4ECDK8CDK19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931683-B1 FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS SCHERING CORP (US) 2011-07-13 EP disclosed
EP-1966220-B1 MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS SCHERING CORP (US) 2011-01-26 EP disclosed
EP-1765829-B1 TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS SCHERING CORP (US) 2010-07-07 EP disclosed
WO-2007024593-A1 FUSED TRICYCLIC MGLUR1 ANTAGONISTS AS THERAPEUTIC AGENTS SCHERING CORPORATION (US) 2007-03-01 WO disclosed
US-20060189639-A1 Antagonists of the mGlu receptor and uses thereof ABBOTT LABORATORIES 2006-08-24 US disclosed
WO-2006002051-A1 TRICYCLIC COMPOUNDS AND THEIR USE AS MGLUR1 ANTAGONISTS SCHERING CORPORATION (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189639-A1 Antagonists of the mGlu receptor and uses thereof GRM3, GRM4, GRIA4 ALDH1A1 1899/4885HTT 1447/4885KDM4E 1588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.